Trials / Completed
CompletedNCT06039189
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area (BSA) Moderate Plaque Psoriasis With Special Site Involvement
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 338 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab | Guselkumab will be administered as subcutaneous injection. |
| DRUG | Placebo | Placebo will be administered as subcutaneous injection. |
Timeline
- Start date
- 2023-08-24
- Primary completion
- 2025-04-14
- Completion
- 2025-04-14
- First posted
- 2023-09-15
- Last updated
- 2025-07-18
Locations
64 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06039189. Inclusion in this directory is not an endorsement.